Replimune Group Files 8-K on Shareholder Votes and Disclosures

Ticker: REPL · Form: 8-K · Filed: 2025-09-04T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, regulatory-disclosure

TL;DR

Replimune filed an 8-K covering shareholder votes and Reg FD disclosures as of Sept 2, 2025.

AI Summary

Replimune Group, Inc. filed an 8-K on September 4, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements. The filing pertains to events on September 2, 2025, with the company's principal executive offices located at 500 Unicorn Park Drive, Woburn, MA.

Why It Matters

This filing provides updates on corporate governance and regulatory disclosures, which are important for investors to understand the company's operational and compliance status.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain material adverse information.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.

What is the primary purpose of this 8-K filing?

The primary purpose is to report on the submission of matters to a vote of security holders, Regulation FD disclosures, and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported was on September 2, 2025.

What is Replimune Group, Inc.'s principal executive office address?

Replimune Group, Inc.'s principal executive office is located at 500 Unicorn Park Drive Suite 303 Woburn, MA 01801.

What is the SEC file number for Replimune Group, Inc.?

The SEC file number for Replimune Group, Inc. is 001-38596.

Filing Stats: 835 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2025-09-04 16:05:40

Key Financial Figures

Filing Documents

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. (a) On September 3, 2025, Replimune Group, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting") to consider and vote on the four proposals set forth below, each of which is described in greater detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on July 25, 2025. (b) The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below. (1) Proposal No. 1 – Election of Class I Directors : The following director nominees were elected to serve as Class I members of the Company's board of directors, each to serve for a three-year term until the Company's 2028 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Philip Astley-Sparke 59,951,241 2,536,881 8,133,506 Kapil Dhingra 52,720,755 9,767,367 8,133,506 Christy Oliger 57,753,910 4,734,212 8,133,506 Joseph Slattery 57,055,805 5,432,317 8,133,506 Michael Goller 62,116,691 371,431 8,133,506 (2) Proposal No. 2 – Ratification of Selection of Independent Registered Public Accounting Firm : The selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026 was ratified. Votes For Votes Against Votes Abstaining 70,375,492 142,326 103,810 (3) Proposal No. 3 – Say on Pay Proposal : The compensation of the Company's named executive officers for the fiscal year ended March 31, 2025 was approved on a non-binding advisory basis. Votes For Votes Against Votes Abstaining Broker Non-Votes 61,212,356 1,250,054 25,712 8,133,506 (4) Proposal No. 4 – Approval of an Amendment to the Company's 2018 Omnibus Incentive Compensation Plan : The proposal to approve an amendment to the Com

01

Item 7.01 Regulation FD Disclosure. On September 2, 2025, the Company issued a news release announcing that a Type A meeting with the U.S. Food and Drug Administration (the "FDA") has been scheduled. A copy of such news release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly stated by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 News Release dated September 2, 2025 104 Cover page interactive data file (formatted as Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIMUNE GROUP, INC. Date: September 4, 2025 By: /s/ Sushil Patel Sushil Patel Chief Executive Officer

View on Read The Filing